Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Sakurako Shimokawa, Kaho Yamamoto, Takahiro Hisai, Masatoshi Fukushima, Kohta Fujiwara, Yoshito Koyanagi, Shoji Notomi, Keijiro Ishikawa, Shoko Tsukamoto, Akie Hirata, Atsushi Takada, Fuyuka Miyahara, Naoki Nakashima, Go Mawatari, Masataka Ishizu, Naoki Toyama, Tomoko Kaida, Kazunori Miyata, Yasuhiro Ikeda, Koh-Hei Sonoda, Yusuke Murakami
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Retinitis pigmentosa
10.1016/s0140-6736(06)69740-7 · 2006
Non-syndromic retinitis pigmentosa
10.1016/j.preteyeres.2018.03.005 · 2018
Gene editing for CEP290-Associated retinal degeneration
10.1056/nejmoa2309915 · 2024
Long-term effect of gene therapy on Leber's congenital amaurosis
10.1056/nejmoa1414221 · 2015
Phase 1/2 AAV5-hRKp.RPGR (Botaretigene sparoparvovec) gene therapy: safety and efficacy in RPGR-Associated X-Linked retinitis pigmentosa
10.1016/j.ajo.2024.05.034 · 2024
Subretinal gene therapy drug AGTC-501 for XLRP phase 1/2 multicenter Study (HORIZON): 24-Month safety and efficacy results
10.1016/j.ajo.2024.11.021 · 2025
Gene editing technology: towards precision medicine in inherited retinal diseases
10.1080/08820538.2021.1887903 · 2021
Advancing clinical trials for inherited retinal diseases: recommendations from the second Monaciano symposium
10.1167/tvst.9.7.2 · 2020
Partial recovery of visual function in a blind patient after optogenetic therapy
10.1038/s41591-021-01351-4 · 2021
Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa
10.1016/j.stem.2023.11.004 · 2023
Gene therapy for inherited retinal degenerations: initial successes and future challenges
10.1088/1741-2552/aa7a27 · 2017
Assessment of visual function with cotoretigene toliparvovec in X-Linked retinitis pigmentosa in the randomized XIRIUS phase 2/3 Study
10.1016/j.ophtha.2024.02.023 · 2024
A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification
10.1007/s10384-023-00986-9 · 2023
Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals
10.1007/s10384-018-0623-4 · 2019
Innate immune response in retinal homeostasis and inflammatory disorders
10.1016/j.preteyeres.2019.100778 · 2020
Neuroinflammation in retinitis pigmentosa: therapies targeting the innate immune system
2022
Neuroinflammation as a therapeutic target in Retinitis Pigmentosa and Quercetin as its potential modulator
10.3390/pharmaceutics13111935 · 2021
Necroptosis and neuroinflammation in retinal degeneration
10.3389/fnins.2022.911430 · 2022
Multiple cytokine analyses of aqueous humor from the patients with retinitis pigmentosa
10.1016/j.cyto.2019.154943 · 2020
Increased aqueous flare is associated with thickening of inner retinal layers in eyes with retinitis pigmentosa
10.1038/srep33921 · 2016
Genetically predicted inflammatory cytokine levels and risk of retinitis pigmentosa
10.1080/13816810.2024.2414081 · 2025
Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa
10.1523/jneurosci.5200-13.2014 · 2014
Relationship between aqueous flare and visual function in retinitis pigmentosa
10.1016/j.ajo.2015.02.001 · 2015
Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa
10.1016/j.ophtha.2012.07.006 · 2013
Correlation between aqueous flare and residual visual field area in retinitis pigmentosa
10.1136/bjophthalmol-2018-312225 · 2019
Aqueous flare and progression of visual field loss in patients with retinitis pigmentosa
10.1167/iovs.61.8.26 · 2020
C-Reactive protein and progression of vision loss in retinitis pigmentosa
10.1111/aos.13502 · 2018
Changes of serum inflammatory molecules and their relationships with visual function in Retinitis pigmentosa
10.1167/iovs.61.11.30 · 2020
Circulating inflammatory monocytes oppose microglia and contribute to cone cell death in retinitis pigmentosa
10.1093/pnasnexus/pgac003 · 2022
Microglial phagocytosis of living photoreceptors contributes to inherited retinal degeneration
10.15252/emmm.201505298 · 2015
Microglial function is distinct in different anatomical locations during retinal homeostasis and degeneration
10.1016/j.immuni.2019.02.007 · 2019
Monocytes in retinal degeneration: little cells with a big impact
10.1007/978-3-031-76550-6_22 · 2025
Peripheral monocytes and neutrophils promote photoreceptor cell death in an experimental retinal detachment model
10.1038/s41419-023-06350-6 · 2023
Microglia versus monocytes: distinct roles in degenerative diseases of the retina
10.1016/j.tins.2020.03.012 · 2020
Microglia regulate neuroglia remodeling in various ocular and retinal injuries
10.4049/jimmunol.1800982 · 2019
Role of fractalkine/CX3CR1 interaction in light-induced photoreceptor degeneration through regulating retinal microglial activation and migration
10.1371/journal.pone.0035446 · 2012
C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa
10.1084/jem.20190009 · 2019
Microglia at sites of atrophy restrict the progression of retinal degeneration via Galectin-3 and Trem2 interactions
2023
Microglia modulation by TGF-beta1 protects cones in mouse models of retinal degeneration
2020
Permanent neuroglial remodeling of the retina following infiltration of CSF1R inhibition-resistant peripheral monocytes
10.1073/pnas.1807123115 · 2018
Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa
10.1111/aos.12293 · doi-reference
Comparison of microperimetry and static perimetry for evaluating macular function and progression in Retinitis pigmentosa
10.1016/j.xops.2024.100582 · doi-reference
Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study
10.1007/s40123-012-0005-9 · doi-reference
Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial
10.1016/j.eclinm.2025.103430 · doi-reference
Endpoints and design for clinical trials in USH2A-Related retinal degeneration: results and recommendations from the RUSH2A natural history Study
10.1167/tvst.13.10.15 · doi-reference
Effect of gene therapy on visual function in Leber's congenital amaurosis
10.1056/nejmoa0802268 · doi-reference
Paleontology. Warm-blooded "sea dragons"?
10.1126/science.1191409 · doi-reference
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)
10.2337/dc10-1407 · doi-reference
Predicting blood loss and transfusion requirement in patients undergoing surgery for musculoskeletal tumors
10.1111/trf.12532 · doi-reference
Dynamic inner blood retina barrier disruption in Retinitis pigmentosa
10.1167/iovs.66.15.61 · doi-reference
Aqueous flare in retinitis pigmentosa
10.1007/s004170050101 · doi-reference
Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation
10.1007/s10792-009-9310-2 · doi-reference
Retinal inflammation, cell death and inherited retinal dystrophies
10.3390/ijms22042096 · doi-reference
Ocular and serum profiles of inflammatory molecules associated with retinitis pigmentosa
10.1167/tvst.13.8.18 · doi-reference
Progression rate of visual function and affecting factors at different stages of retinitis pigmentosa
10.1155/2022/7204954 · doi-reference
Multimodal structural disease progression of retinitis pigmentosa according to mode of inheritance
10.1038/s41598-019-47251-z · doi-reference
EYS mutations causing autosomal recessive Retinitis pigmentosa: changes of retinal structure and function with disease progression
10.3390/genes8070178 · doi-reference
Long-term natural history of ellipsoid zone width in USH2A-retinopathy
10.1136/bjo-2024-325323 · doi-reference
Establishing clinical trial endpoints in selecting patients for RPGR retinal gene therapy
10.1167/tvst.13.9.18 · doi-reference
Clinical characteristics of EYS-associated retinal dystrophy in 291 Japanese patients
10.1038/s41525-025-00541-0 · doi-reference
Natural history of retinitis pigmentosa based on genotype, vitamin A/E supplementation, and an electroretinogram biomarker
10.1172/jci.insight.167546 · doi-reference
Central retinal sensitivity decline in RPGR-Related retinal phenotypes
10.1016/j.ajo.2025.11.002 · doi-reference
PDE6A-Associated retinitis pigmentosa, clinical characteristics, genetics, and natural history
10.1016/j.oret.2024.08.018 · doi-reference
Genetics, clinical characteristics, and natural history of PDE6B-Associated retinal dystrophy
10.1016/j.ajo.2024.02.005 · doi-reference
Clinical characteristics and natural history of rho-associated retinitis pigmentosa: a long-term Follow-Up Study
10.1097/iae.0000000000002808 · doi-reference
Assessment of central visual function in patients with retinitis pigmentosa
10.1038/s41598-018-26231-9 · doi-reference
Baseline relationships between visual function and inflammatory markers in the registry of moderated-stage retinitis pigmentosa
10.1016/j.xops.2025.100930 · doi-reference
Study protocol for a prospective natural history registry investigating the relationships between inflammatory markers and disease progression in retinitis pigmentosa: the RP-PRIMARY study
10.1007/s10384-025-01179-2 · doi-reference
The role of microglia and peripheral monocytes in retinal damage after corneal chemical injury
10.1016/j.ajpath.2018.03.005 · doi-reference